Marker Therapeutics (MRKR) Common Equity (2010 - 2026)
Marker Therapeutics' Common Equity was $12.17 million in Q2 2026, up 16.0% from $10.49 million a year earlier but down 11.8% from the prior quarter.
Marker Therapeutics (MRKR) Common Equity (2010 - 2026) Analysis & Trends
At the end of FY2025, Common Equity at Marker Therapeutics came in at $16.8 million, down 9.5% from FY2024.
- Common Equity shows a five-year compound annual growth rate of -9.3% (FY2020 to FY2025).
- In earlier years, Common Equity was $18.56 million in FY2024 (+32.1%), $14.05 million in FY2023 (-28.3%), $19.6 million in FY2022 (-55.4%) and $43.99 million in FY2021 (+60.9%).
- Quarterly Common Equity has moved between $7.45 million (Q3 2024) and $52.28 million (Q3 2021) over five years.
- Compared with a year earlier, Common Equity was higher in five of the last eight quarters, with growth averaging 19.5%.
- The best year-over-year quarter for Common Equity over five years was Q3 2025 (growth of 146.8%); the worst was Q3 2022 (a decline of 56.8%).
- Per Business Quant data, MRKR's Common Equity in the three quarters before Q2 2026 was $13.8 million (Q1 2026), $16.8 million (Q4 2025) and $18.39 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 41.98 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 20.25 Bn |
| 10 | Marker Therapeutics | 17.87 Mn | -42.04 Mn | - | 12.17 Mn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12.17 Mn |
| Mar 31, 2026 | 13.80 Mn |
| Dec 31, 2025 | 16.80 Mn |
| Sep 30, 2025 | 18.39 Mn |
| Jun 30, 2025 | 10.49 Mn |
| Mar 31, 2025 | 14.49 Mn |
| Dec 31, 2024 | 18.56 Mn |
| Sep 30, 2024 | 7.45 Mn |
| Jun 30, 2024 | 9.70 Mn |
| Mar 31, 2024 | 11.79 Mn |
| Dec 31, 2023 | 14.05 Mn |
| Sep 30, 2023 | 16.71 Mn |
| Jun 30, 2023 | 19.03 Mn |
| Mar 31, 2023 | 15.91 Mn |
| Dec 31, 2022 | 19.60 Mn |
| Sep 30, 2022 | 22.60 Mn |
| Jun 30, 2022 | 28.03 Mn |
| Mar 31, 2022 | 35.71 Mn |
| Dec 31, 2021 | 43.99 Mn |
| Sep 30, 2021 | 52.28 Mn |
Marker Therapeutics Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=MRKR&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "MRKR", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=MRKR&period=max&api_key=YOUR_API_KEY");
const data = await res.json();